LIGAND PHARMACEUTICALS INCORPORATED (LGND) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 290.54M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $290.54M | (m) | (m) |
| 2026-03-31 | (m) | $274.48M | (m) | (m) |
| 2025-12-31 | (m) | $268.09M | (m) | (m) |
| 2025-09-30 | (m) | $251.23M | (m) | (m) |
| 2025-06-30 | (m) | $187.58M | (m) | (m) |
| 2025-03-31 | (m) | $181.49M | (m) | (m) |
| 2024-12-31 | (m) | $167.13M | (m) | (m) |
| 2024-09-30 | (m) | $152.42M | (m) | (m) |
| 2024-06-30 | (m) | $133.48M | (m) | (m) |
| 2024-03-31 | (m) | $118.31M | (m) | (m) |
| 2023-12-31 | (m) | $131.31M | (m) | (m) |
| 2023-09-30 | (m) | $153.59M | (m) | (m) |
| 2023-06-30 | (m) | $179.95M | (m) | (m) |
| 2023-03-31 | (m) | $203.71M | (m) | (m) |
| 2022-12-31 | (m) | $196.25M | (m) | (m) |
| 2022-09-30 | (m) | $241.67M | (m) | (m) |
| 2022-06-30 | (m) | $240.42M | (m) | (m) |
| 2022-03-31 | (m) | $267.68M | (m) | (m) |
| 2021-12-31 | (m) | $277.13M | (m) | (m) |
| 2021-09-30 | (m) | $274.65M | (m) | (m) |
| 2021-06-30 | (m) | $251.66M | (m) | (m) |
| 2021-03-31 | (m) | $208.41M | (m) | (m) |
| 2020-12-31 | (m) | $186.42M | (m) | (m) |
| 2020-09-30 | (m) | $143.43M | (m) | (m) |
| 2020-06-30 | (m) | $126.39M | (m) | (m) |
| 2020-03-31 | (m) | $109.96M | (m) | (m) |
| 2019-12-31 | (m) | $120.28M | (m) | (m) |
| 2019-09-30 | (m) | $152.87M | $12.37M | (m) |
| 2019-06-30 | (m) | $173.72M | $10.68M | (m) |
| 2019-03-31 | (m) | $238.78M | $9.41M | (m) |
| 2018-12-31 | (m) | $251.45M | $6.34M | (m) |
| 2018-09-30 | (m) | $150.23M | $5.12M | (m) |
| 2018-06-30 | (m) | $162.51M | $6.04M | (m) |
| 2018-03-31 | (m) | $167.99M | (m) | (m) |
| 2017-12-31 | (m) | $141.10M | (m) | (m) |
| 2017-09-30 | (m) | $128.82M | (m) | (m) |
| 2017-06-30 | (m) | $117.07M | (m) | (m) |
| 2017-03-31 | (m) | $108.59M | (m) | (m) |
| 2016-12-31 | (m) | $108.97M | (m) | (m) |
| 2016-09-30 | (m) | $91.98M | (m) | (m) |
| 2016-06-30 | (m) | $88.06M | (m) | (m) |
| 2016-03-31 | (m) | $86.96M | (m) | (m) |
| 2015-12-31 | (m) | $71.91M | (m) | (m) |
| 2015-09-30 | (m) | $73.72M | (m) | (m) |
| 2015-06-30 | (m) | $70.99M | (m) | (m) |
| 2015-03-31 | (m) | $63.18M | (m) | (m) |
| 2014-12-31 | (m) | $64.54M | (m) | (m) |
| 2014-09-30 | (m) | $56.27M | (m) | (m) |
| 2014-06-30 | (m) | $54.31M | (m) | (m) |
| 2014-03-31 | (m) | $53.28M | (m) | (m) |
| 2013-12-31 | (m) | $48.97M | (m) | (m) |
| 2013-09-30 | (m) | $47.87M | (m) | (m) |
| 2013-06-30 | (m) | $41.24M | (m) | (m) |
| 2013-03-31 | (m) | $37.40M | (m) | (m) |
| 2012-12-31 | (m) | $31.39M | (m) | (m) |
| 2012-09-30 | (m) | $30.69M | (m) | (m) |
| 2012-06-30 | (m) | $30.06M | (m) | (m) |
| 2012-03-31 | (m) | $31.78M | (m) | (m) |
| 2011-12-31 | (m) | $30.04M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $23.54M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $38.94M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.